Načítá se...
A multicentre trial of recombinant growth hormone and low dose oestrogen in Turner syndrome: near final height analysis
BACKGROUND—Turner syndrome accounts for 15-20% of childhood usage of growth hormone (GH) in the UK but final height benefit remains uncertain. The most effective strategy for oestrogen replacement is also unclear. METHODS—Fifty eight girls who, at start of treatment, were of mean age 9.1 years and p...
Uloženo v:
| Hlavní autoři: | , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Group
2001
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1718629/ https://ncbi.nlm.nih.gov/pubmed/11124794 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/adc.84.1.76 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|